Part II | Chapter 8 174 Supplementary B Additional variables used for multiple imputation via chained equations: § Primary treatment - EBRT - LDR brachytherapy - HDR brachytherapy § Pelvic lymph node dissection at primary treatment (yes/no) § Initial NCCN risk group - Low-risk (T1-T2a AND Gleason £ 6 AND PSA < 10.0 ng/mL) - Intermediate-risk (T2b-T2c OR Gleason 7 OR PSA 10.0-20.0 ng/mL) - High-risk (³ T3a OR Gleason ³ 8 OR PSA > 20.0 ng/mL) § ADT use - No - £ 36 months - >36 months § PSA nadir post-primary treatment (ng/mL) § Prostate size on pre-salvage MRI (cm3) § Maximum tumour diameter on pre-salvage MRI (mm) § V200% CTV (%) § PSA velocity (ng/mL/years) § Interval between primary and salvage treatment (months) § Previous salvage treatment (yes/no) § Time to nadir post-primary treatment (months) § Deceased (yes/no) Legend: EBRT = External beam radiation therapy. LDR = Low-dose-rate. HDR = High-dose-rate. NCCN = National Comprehensive Cancer Network. PSA = Prostate-specific antigen. ADT = Androgen deprivation therapy. CTV = Clinical Target Volume. V200% = Volume receiving 200% of the prescribed dose.
RkJQdWJsaXNoZXIy MTk4NDMw